drugset / Trial / NCT01372449
A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)
Phase 2
Completed
23 enrolled
Evdokia Anagnostou
Icahn School of Medicine at Mount Sinai · collabNationwide Children's Hospital · collabRush University Medical Center · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will attempt to study the effect of memantine, on memory, and motor praxis/expressive language skills in children with autism. The investigators will recruit children ages 6-12 years who are verbal and meet criteria for Autism Spectrum Disorder. The children will be assessed for memory function, expressive language output and motor skills/praxis. They will then be randomized to memantine or placebo for 6 months. The effects of this medication and its safety in this population will be studied over the 6 month period.
Timeline
- Start
- 2011-12
- Primary completion
- 2015-10
- Completion
- 2015-10
Publications
- Brignell A, Marraffa C, Williams K, May T. Memantine for autism spectrum disorder. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013845. doi: 10.1002/14651858.CD013845.pub2.
- Soorya LV, Fogg L, Ocampo E, Printen M, Youngkin S, Halpern D, Kolevzon A, Lee S, Grodberg D, Anagnostou E. Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2021 Sep;31(7):475-484. doi: 10.1089/cap.2021.0010.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Memantine | Unknown | 6 mg | — |
| Comparator | Memantine | Unknown | 9 mg | — |
| Comparator | Memantine | Unknown | 12 mg | — |